Freudenberg Medical has announced plans to expand its drug-device combination products business with a new production facility. The company has invested over $50 million in a new Hemoteq AG production facility in Aachen, Germany.
 
Freudenberg Medical acquired Hemoteq in 2015, expanding its portfolio to include drug-coating solutions for balloon catheters and stents as well as hydrophilic coatings.
 
“The convergence of medical devices and drugs is inspiring a new generation of innovative products that fundamentally improve patients’ outcomes,” says Dr. Mark Ostwald, CEO of Freudenberg Medical. “With this innovation-driven investment, we are strengthening our position as a strategic partner to our customers, offering vertically integrated solutions along the entire supply chain.” 
 
The new facility will triple Freudenberg’s manufacturing footprint in Alsdorf. The 130,000-square-foot facility will include ISO Class 7 cleanrooms, laboratories, and offices to offer research, development, and production capabilities.
 
The existing industrial building at the site is being converted to meet medical technological, environmental, and energy efficiency standards. A company-owned PV solar power plant will generate the energy needed to operate the site, energy recovery from the exhaust air of the clean rooms will be used for heating, and an existing oil tank will be converted into a cistern for rainwater utilization.
 
The first employees have been working at the new site since April 2024 and it will be fully occupied by the end of 2026.